We haven’t heard anything about this indication for quite some time. I thought that the placebo arm were to be treated?
Excitement was brewing at the time but all is quiet. Did Any Lightners deflection to a competitor put a hold on proceedings?
While Direct Biologics power on with their trial, are we left doing nothing about it?
Or is it possible that MSB have a strategy in place to extend Rem-l to this indication once approved for GVHD to bring in some $$ to help fund further trials?
Does anyone know if a label extension is possible for UC and Crohns?
We haven’t heard anything about this indication for quite some...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.010(1.09%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 94.0¢ | 89.5¢ | $4.970M | 5.436M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18877 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 6795 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |